Catalog Home Page

The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications

Moran, E.M. and Mastaglia, F.L. (2014) The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscular Disorders, 24 (11). pp. 943-952.

[img]
Preview
PDF - Authors' Version
Download (596kB)
Link to Published Version: http://dx.doi.org/10.1016/j.nmd.2014.06.432
*Subscription may be required

Abstract

The idiopathic inflammatory myopathies are a heterogeneous group of autoimmune muscle disorders with distinct clinical and pathological features and underlying immunopathogenic mechanisms. Traditionally, CD4+ Th1 cells or CD8+ cytotoxic effector T cells and type I/II interferons have been primarily implicated in the pathogenesis of the inflammatory myopathies. The presence of IL-17A producing cells in the inflamed muscle tissue of myositis patients and the results of in vitro studies suggest that IL-17A and the Th17 pathway may also have a key role in these diseases. The contribution of IL-17A to other chronic inflammatory and autoimmune diseases has been well established and clinical trials of IL-17A inhibitors are now at an advanced stage. However the precise role of IL-17A in the various forms of myositis and the potential for therapeutic targeting is currently unknown and warrants further investigation.

Publication Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Elsevier BV
Copyright: © 2014 Elsevier B.V.
URI: http://researchrepository.murdoch.edu.au/id/eprint/23259
Item Control Page Item Control Page

Downloads

Downloads per month over past year